Evolution of baseline characteristics and severe outcomes in COVID-19 inpatients during the first and second waves in Northeastern France - 26/01/22
, M. Eyriey b, S. Gravier a, D. Kayser a, C. Ion a, M. Mohseni-Zadeh a, J.C. Ongagna b, A. Schieber b, C. Kempf bthe
Centre Alsace Study Group1
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Highlights |
• | Patients hospitalized with COVID-19 during the second wave of the epidemics were associated with a shorter time between symptom onset and hospitalization, milder symptoms at admission, and higher steroid prescriptions compared with patients of the first epidemic wave. |
• | Patients of the second epidemic wave had a lower death rate and fewer ICU hospitalizations than patients of the first epidemic wave. |
• | Except for cardiovascular events, which were more frequently observed during the second epidemic wave, there was no change in other extrapulmonary complications during the two epidemic waves. |
Abstract |
Objectives |
Two COVID-19 epidemic waves occurred in France in 2020. This single-center retrospective study compared patients’ characteristics and outcomes.
Patients and methods |
We included all patients with confirmed COVID-19 admitted to Colmar Hospital in March (n=600) and October/November (n=205) 2020.
Results |
Median ages, sex ratio, body mass index, and number of comorbidities were similar in wave 1 and 2 patients. Significant differences were found for temperature (38°C vs. 37.2), need for oxygen (38.6% vs. 26.8%), high-flow cannula (0% vs. 8.3%), and steroid use (6.3% vs. 54.1%). Intensive care unit (ICU) hospitalizations (25.5% vs. 15.1%, OR: 0.44, 95% CI [0.28; 0.68], P=0.002) and deaths (19.2% vs. 12.7%, OR: 0.61, 95% CI [0.37; 0.98], P=0.04) decreased during the second wave. Except for cardiovascular events (5.5% vs. 10.2%), no change was observed in extrapulmonary events.
Conclusions |
Deaths and ICU hospitalizations were significantly reduced during the second epidemic wave.
Le texte complet de cet article est disponible en PDF.Keywords : COVID-19, SARS-CoV-2, Outcome, Extrapulmonary complications, COVID waves
Plan
Vol 52 - N° 1
P. 35-39 - février 2022 Retour au numéro
Article précédent
- Tocilizumab and COVID-19: Timing of administration assessment
- Q. Richier, V. Jachiet, V. Bonnemains, L. Plaçais, N. Abisror, M. Garnier, J. Pacanowski, R. Dhote, O. Hinchschberger, M. Michel, B. Bienvenu, C. Comarmond, K. Lacombe, A. Mekinian
- Vaccine effectiveness against COVID-19 hospitalization in adults in France: A test negative case control study
- Liem Binh Luong Nguyen, Rebecca Bauer, Zineb Lesieur, Florence Galtier, Xavier Duval, Philippe Vanhems, Fabrice Lainé, Pierre Tattevin, Christine Durier, Odile Launay, FLUVAC Study group
Bienvenue sur EM-consulte, la référence des professionnels de santé.